Revlimid^® Wave 3 Tracking Survey; Trends in Usage in Multiple Myeloma and myelodysplastic syndrome

A Survey of Fifty One Oncologists and Hematologists

November-December 2007 (Wave 2: Feb 2007, Wave 1: Dec 2006)

December 2007

Description: Survey with key findings.

Study Description:

Topic	Revlimid
Respondent Type	Oncology/Hematology
Specialty	Medical Oncology (n = 5), Hematology/Oncology (n = 46)
Region	United States only
Methodology	Online survey, self-administered via a Panel Intelligence website §    Duration: 30 minutes §    Size: 51 respondents §    Fielding dates: November 28 to December 2, 2007

Objectives:

§    Determine the current market share held by Revlimid and other medications for MDS/MM patients.

§    Evaluate Revlimid based on physician and patient opinions.

§    Anticipate the future use and changes from current use of Revlimid.

§    Reveal side effects and cost issues Revlimid patients experience.

Products Mentioned in This Report:

Company	Ticker Symbol	Product(s)
Celgene	CELG	Revlimid
Millennium	MLNM	Velcade

Inclusion Criteria and Respondent Demographics:

Inclusion Criteria

§    Board-certified or eligible Oncologist or Hematologist §    In practice between 2 and 30 years §    Spends at least 75% of professional time in clinical practice §    Have prescribed Revlimid for at least 10 MM and/or MDS patients

 

Comments on this report

There are no comments for this entry yet.

Leave a comment